Middle Molecule Find

Rulebook › V-tags › V506

V506 Assessment: immunizations and medications

Written V0506 on the CMS-2567 and in QCOR.

Enforces 42 CFR 494.80(a)(3) · Appendix H Rev. 246, page 214 · checked 12 Nov 2026

Cited on this tag? What happens after a citation · One-page sheet for the binder

The regulation

§ 494.80(a) Standard: Assessment criteria. The patient’s comprehensive assessment must include, but is not limited to, the following: (3) …immunization history, and medication history.

Read 42 CFR 494.80 on the eCFR

CMS's interpretive guidance

Interpretive Guidance §494.80(a)(3)

Note: this guidance is a continuation of the requirement at §494.80(a)(3) “Immunization history” should include documentation of (1) standard immunizations received, such as pneumococcal, Hepatitis, and influenza, (2) vaccinations that result from emerging infectious diseases such as COVID-19 vaccination, and (3) screenings for infectious diseases such as tuberculosis. The immunization record is expected to include at least the patient’s immunization history as of the effective date of this regulation.

The Centers for Disease Control and Prevention (CDC) recommends that all dialysis patients:

  • Be screened for TB on or before the first dialysis treatment and be rescreened if TB exposure is detected. The frequency of TB screening should be based on a facility’s risk assessment, including the community’s TB profile. If the facility is located in an area with a high incidence of TB, screening may be indicated more frequently.

The CDC recommends that the two-step Mantoux skin test be used for baseline testing to reduce the likelihood of mistaking a booster reaction for a new infection. The interferon gamma release assay (IGRA) is a fairly new method for TB surveillance and can be used as an alternative testing method, with each facility evaluating the benefits and indications for its use. The advantages of IGRA include the availability of results within 24 hours and the elimination of the probability of a boosted reaction on subsequent testing.

  • Chest X-rays are acceptable to rule out active TB disease but may not properly identify exposure to TB or latent TB infections. See additional information regarding CDC recommendations for TB testing on the CDC website at: https://www.cdc.gov/tb/topic/testing/default.htm.
  • Be offered influenza and pneumococcal vaccine and have immunization histories for these vaccines be tracked. Both are universally recommended for this population and relate directly to infection control issues.
  • The CDC expectations for Hepatitis vaccinations are detailed at V126 and V127. “Medication history” should include a review of the patient’s allergies and of all medications that the patient is taking, including over-the-counter medications and supplements. The assessment should demonstrate that all current medications were reviewed for possible adverse effects/interactions and continued need.

Verbatim from Appendix H Rev. 246, with CMS's headings, lists and bold. Check page 214 (the full 469-page PDF) before quoting it.

Connected tags

Tags whose guidance points here